Abundant expression of HMGB1 in human T-cell lymphotropic virus type I-infected T-cell lines and high plasma levels of HMGB1 in patients with adult T-cell leukemia

Kimura, Ryuichiro; Mori, Nozomu

doi:10.3892/ol.2014.1851

Cited by 14 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our data showed that HMGB1 and HMGB2 were more abundant in samples from HTLV-1-infected individuals, markedly in HAM/TSP patients (Supplemental Table 1 ). According to literature, HMGB1 levels are also increased in ATLL patients and HTLV-1-infected cell lines 33 , which corroborates our findings.…”

Section: Resultssupporting

confidence: 93%

Protein Profile of Blood Monocytes is Altered in HTLV-1 Infected Patients: Implications for HAM/TSP Disease

Echevarria-Lima

Pereira

Oliveira

et al. 2018

Sci Rep

View full text Add to dashboard Cite

Human T-cell lymphotropic virus type-1 (HTLV-1) is the etiological agent of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). The endothelial breakdown and migration of leukocytes, including monocytes, to the spinal cord are involved in HAM/TSP development. Monocytes from HTLV-1-infected individuals exhibit important functional differences when compared to cells from uninfected donors. Using proteomic shot gun strategy, performed by nanoACQUITY-UPLC system, we analyzed monocytes isolated from peripheral blood of asymptomatic carriers (AC), HAM/TSP and uninfected individuals. 534 proteins were identified among which 376 were quantified by ExpressionE software. Our study revealed a panel of changes in protein expression linked to HTLV-1 infection. Upregulation of heat shock proteins and downregulation of canonical histone expression were observed in monocytes from HTLV-1-infected patients. Moreover, expression of cytoskeleton proteins was increased in monocytes from HTLV-1-infected patients, mainly in those from HAM/TSP, which was confirmed by flow cytometry and fluorescence microscopy. Importantly, functional assays demonstrated that monocytes from HAM/TSP patients present higher ability for adhesion and transmigration thought endothelium than those from AC and uninfected individuals. The major changes on monocyte protein profile were detected in HAM/TSP patients, suggesting that these alterations exert a relevant role in the establishment of HAM/TSP.

show abstract

Section: Resultssupporting

confidence: 93%

Protein Profile of Blood Monocytes is Altered in HTLV-1 Infected Patients: Implications for HAM/TSP Disease

Echevarria-Lima

Pereira

Oliveira

et al. 2018

Sci Rep

View full text Add to dashboard Cite

show abstract

“…After treatment with the HMGB1 inhibitor glycyrrhiza, the invasion and metastatic abilities of lymphoma cells were significantly decreased [139]. Adult T cell leukemia (ATL) patients have high plasma HMGB1 levels compared with normal controls [140]. It has been reported that high plasma HMGB1 levels in patients with ATL are caused by infection with human T cell lymphotropic virus type I (HTLV-I) [141].…”

Section: Lymphomamentioning

confidence: 99%

High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies

et al. 2020

View full text Add to dashboard Cite

High mobility group box 1 (HMGB1) is a nonhistone chromatin-associated protein that has been widely reported to play a pivotal role in the pathogenesis of hematopoietic malignancies. As a representative damage-associated molecular pattern (DAMP), HMGB1 normally exists inside cells but can be secreted into the extracellular environment through passive or active release. Extracellular HMGB1 binds with several different receptors and interactors to mediate the proliferation, differentiation, mobilization, and senescence of hematopoietic stem cells (HSCs). HMGB1 is also involved in the formation of the inflammatory bone marrow (BM) microenvironment by activating proinflammatory signaling pathways. Moreover, HMGB1-dependent autophagy induces chemotherapy resistance in leukemia and multiple myeloma. In this review, we systematically summarize the emerging roles of HMGB1 in carcinogenesis, progression, prognosis, and potential clinical applications in different hematopoietic malignancies. In summary, targeting the regulation of HMGB1 activity in HSCs and the BM microenvironment is highly beneficial in the diagnosis and treatment of various hematopoietic malignancies.

show abstract

“…Malignancies of B-cell origin were the most commonly studied, including non-Hodgkin’s lymphoma (NHL) [ 19 – 21 ] and lymphocytic leukaemias [ 22 – 24 ]. A minority of studies investigated HMGB1 and RAGE in T-cell malignancies [ 25 , 26 ] and acute myeloid leukaemia (AML) [ 27 , 28 ].…”

Section: Resultsmentioning

confidence: 99%

“…Two included studies investigated the clinical value of HMGB1 in T-cell-derived haematological malignancies [ 25 , 26 ]. Plasma HMGB1 levels collected upon admission from patients diagnosed with adult T-cell leukaemia tended to be higher than those of healthy donors ( p = 0.051) [ 25 ]. While this study was affected by a small sample size (total, n = 13), the mean level of HMGB1 in patients with T-cell leukaemias was over ten-fold higher than that of healthy donors.…”

Section: Resultsmentioning

confidence: 99%

Association of high mobility group BOX-1 and receptor for advanced glycation endproducts with clinicopathological features of haematological malignancies: a systematic review

Nguyen

Bhavsar

Riley

et al. 2016

View full text Add to dashboard Cite

High-mobility group box 1 (HMGB1) is a versatile protein with nuclear and extracellular functions. In the extracellular milieu, HMGB1 binds to several receptors, notably the receptor for advanced glycation end-products (RAGE). The expressions of HMGB1 and RAGE have been described in a variety of cancers. However, the clinical values of HMGB1 and RAGE in haematological malignancies have yet to be evaluated. A systematic search through PubMed and the Web of Science for articles discussing the role of HMGB1 and RAGE in haematological malignancies produced 15 articles. Overexpression of HMGB1 was reported to be associated with malignancy and, in certain studies, poor prognosis and tumour aggressiveness. Only one included study investigated the clinical value of RAGE, in which no significant difference was found between expression of RAGE in CLL neoplastic cells and nonmalignant controls. The discussed associations of HMGB1 and RAGE with clinicopathological characteristics of patients with haematological malignancies warrants further investigation into the prognostic and diagnostic value of both of these molecules.

show abstract

Abundant expression of HMGB1 in human T-cell lymphotropic virus type I-infected T-cell lines and high plasma levels of HMGB1 in patients with adult T-cell leukemia

Cited by 14 publications

References 23 publications

Protein Profile of Blood Monocytes is Altered in HTLV-1 Infected Patients: Implications for HAM/TSP Disease

Protein Profile of Blood Monocytes is Altered in HTLV-1 Infected Patients: Implications for HAM/TSP Disease

High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies

Association of high mobility group BOX-1 and receptor for advanced glycation endproducts with clinicopathological features of haematological malignancies: a systematic review

Contact Info

Product

Resources

About